Assembly Biosciences Balance Sheet Health
Financial Health criteria checks 6/6
Assembly Biosciences has a total shareholder equity of $41.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $136.8M and $95.7M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$130.25m |
| Equity | US$41.10m |
| Total liabilities | US$95.73m |
| Total assets | US$136.82m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: V7B's short term assets ($133.8M) exceed its short term liabilities ($39.2M).
Long Term Liabilities: V7B's short term assets ($133.8M) exceed its long term liabilities ($56.5M).
Debt to Equity History and Analysis
Debt Level: V7B is debt free.
Reducing Debt: V7B has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable V7B has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: V7B is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 3.3% per year.